April 14, 2025

FDA Clears Tablet for Cholestatic Pruritus

The FDA has approved a tablet formulation of maralixibat (LIVMARLI) for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

Conexiant

April 14, 2025

FDA-Approved COVID-19 Drugs: Safety Risks Assessed

Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.

Conexiant

April 14, 2025

Inebilizumab Effective for Myasthenia Gravis

CD19+ B-cell-depleting therapy shows significant improvement in function and disease severity in phase III trial of autoimmune neuromuscular disorder.

Conexiant

April 14, 2025

Pfizer Halts Danuglipron Obesity Pill Trials

Pfizer discontinues development of potential weight-loss drug due to liver injury in trial participant, impacting stock prices and future strategies.

Reuters

April 11, 2025

New Self-Injection Option for gMG, CIDP

A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 10, 2025

FDA Clears Stapler for Single-Port Surgery

The FDA has cleared Intuitive’s SP SureForm 45 stapler, the first stapler designed for single-port robotic surgery using the da Vinci SP system.

Conexiant

April 09, 2025

Dual Immunotherapy Approved for Advanced CRC

The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.

Conexiant

April 09, 2025

22 Drugs Tied to Melasma

Researchers identified 22 drugs, primarily hormonal agents, associated with melasma.

Conexiant